

Lentil Lectin, A Molecularly Engineered from *Lens culinaris*: A Broad-Spectrum Activities Against SARS-CoV-2 (COVID-19)

Attapon Cheepsattayakorn^{1,3*}, Ruangrong Cheepsattayakorn² and Porntep Siriwanarangsun³

¹10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand

²Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

³Faculty of Medicine, Western University, Pathumtani Province, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Recently, a study demonstrated an engineered banana lectin (BanLec, *Lens culinaris*) that importantly decreased mitogenicity by replacing histidine 84 with a threonine (H84T-BanLec) and introduction of a single amino acid substitution [1]. H84T-BanLec demonstrated potent broad-spectrum against viruses high-mannose N-glycans (particularly oligomannose-type glycans and GlcNAc at the non-reducing end terminus and artificial mutants at N-/O-linked glycosylation with most potent and broad antiviral activity against the epidemic variants B.1.1.7, B.1.351, and P.1 [2]), such as severe-acute-respiratory-syndrome coronavirus (SARS-CoV-2 (COVID-19)) and middle-east-respiratory-syndrome coronavirus (MERS-CoV) *in vitro* and *in vivo*, in addition to Ebola virus, human immunodeficiency viruses 1 and 2, hepatitis C virus, and influenza viruses A and B, via highly-glycosylated-viral proteins for blocking the cell attachment, cell entry, fusion of membrane, and coronavirus replication [1,3-5]. At 1 mg/mL, lentil lectin revealed no cytotoxic activity and weak hemagglutination [2]. In mouse model, with single injection, no weight loss was identified [2]. Lentil lectin could block inhibit the binding of the human anti-converting-enzyme-2 (ACE 2) receptors to SARS-CoV-2 (COVID-19)-S-trimer protein [2,6] (Figure 1).

In conclusion, lentil lectin demonstrated strong evidence of blocking SARS-CoV-2 (COVID-19) variant infection for development of worthy future strategies of SARS-CoV-2 (COVID-19) variant management.

Received: October 17, 2022

Published: November 01, 2022

© All rights are reserved by Attapon Cheepsattayakorn., et al.




Figure 1: Demonstrating the mechanism of H84T-BanLec in blocking viral entry with protection against SARS-CoV-2 (COVID-19) and MERS-CoV infections *in vivo*.

(Source: Zhu R, Hain L, Seferovic H, Tampe' R, Kai-Wang To K., et al. A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-Co-2 and MERS-CoV infection *in vivo*. Cell Reports Medicine 2022; 3: 100774. DOI: <https://doi.org/10.1016/j.xcrm.2022.100774>)

Bibliography

1. Boudreaux DM., *et al.* "Engineering a therapeutic lectin by uncoupling mitogenicity from antiviral activity". *Cell* 163 (2015): 746-758.
2. Wang W., *et al.* "Lentil lectin derived from *Lens culinaris* exhibit broad antiviral activities against SARS-CoV-2 variants". *Emerging Microbes and Infection* 10 (2021): 1519-1529.
3. Swanson MD., *et al.* "A lectin isolated from bananas is a potent inhibitor of HIV replication". *Journal of Biological Chemistry* 285 (2010): 8646-8655.
4. Coves-Datson EM., *et al.* "A molecularly engineered antiviral banana lectin inhibits fusion and is efficacious against influenza virus infection *in vivo*". *Proceedings of the National Academy of Sciences of the United States of America* 117 (2020): 2122-2132.
5. Coves-Datson EM., *et al.* "Inhibition of Ebola virus by a molecularly engineered banana lectin". *PLOS Neglected Tropical Diseases* 13 (2019): e0007595.
6. Zhu R., *et al.* "A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-Co-2 and MERS-CoV infection *in vivo*". *Cell Reports Medicine* 3 (2022): 100774.